AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7092487 — intervention group
Group type: COMPARATOR
Intervention: Bipolar illness patients
Number of subjects: 39
Study 7092487 — intervention group
Group type: COMPARATOR
Intervention: Unipolar illness patients
Number of subjects: 39
Study 31439877 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week supervised preoperative rehabilitation program
Number of subjects: 65
Study 31439877 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 65
Study 30004577 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder + FIT
Number of subjects: 2144
Study 30004577 — intervention group
Group type: COMPARATOR
Intervention: Reminder
Number of subjects: 2144
Study 26908704 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin (10 μg/kg, once per week)
Number of subjects: 77
Study 26908704 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (400 U/kg, 3 times/week)
Number of subjects: 77
Study 26908704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 26908704 — intervention group
Group type: COMPARATOR
Intervention: Term Controls (TCs)
Number of subjects: 77
Study 24957712 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy treatment for neck pain
Number of subjects: 181
Study 23118893 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TSH levels (Q5)
Number of subjects: 402
Study 23118893 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroid status
Number of subjects: 402
Study 23118893 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthyroid status
Number of subjects: 402
Study 19121976 — intervention group
Group type: EXPERIMENTAL
Intervention: Static condition with masseteric excitation at 20%, 40%, 60%, 80%, or 100%
Number of subjects: 14
Study 19121976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic condition with habitual chewing pace and stimuli delivered at predetermined gape
Number of subjects: 14
Study 19121976 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to mildly painful stimuli during dynamic condition
Number of subjects: 14
Study 19121976 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to moderately painful stimuli during dynamic condition
Number of subjects: 14
Study 17537023 — intervention group
Group type: EXPERIMENTAL
Intervention: HL‐350
Number of subjects: 20
Study 17537023 — intervention group
Group type: COMPARATOR
Intervention: Control milk (HL‐00)
Number of subjects: 20
Study 15157727 — intervention group
Group type: EXPERIMENTAL
Intervention: Program of Resources, Information and Support for Mothers (PRISM)
Number of subjects: 6400
Study 15157727 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (not specified)
Number of subjects: 6400
Study 11141226 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiamazole
Number of subjects: 100
Study 11141226 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 100
Study 11141226 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 100
Study 11141226 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockade (general)
Number of subjects: 100
Study 9847269 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of the preventive therapy study
Number of subjects: 4058
Study 9847269 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD positive subjects
Number of subjects: 4058
Study 9847269 — intervention group
Group type: EXPERIMENTAL
Intervention: MTBCF-stimulated IFN-gamma levels
Number of subjects: 4058
Study 8018457 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II infusion (1 ng min‐1 kg‐1)
Number of subjects: 8
Study 8018457 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (200 mg)
Number of subjects: 8
Study 8018457 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin pre‐treatment followed by angiotensin II infusion
Number of subjects: 8
Study 8018457 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (20 mg) administration
Number of subjects: 8
Study 2529659 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheeting applied for 8 weeks (at least 12 hours a day)
Number of subjects: 10
Study 2529659 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheeting
Number of subjects: 10
Study 2529659 — intervention group
Group type: COMPARATOR
Intervention: Control scars (untreated, mirror-image or adjacent)
Number of subjects: 10
Study 983797 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon absorptiometry for evaluating bone mineral content
Number of subjects: 73
Study 983797 — intervention group
Group type: COMPARATOR
Intervention: Conventional X-ray film evaluation of bone mineral
Number of subjects: 73
Study 31704711 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 0
Study 31704711 — intervention group
Group type: COMPARATOR
Intervention: Control (no progesterone)
Number of subjects: 0
Study 28545525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tensor group (gap-tensioning device set at 20 lbf)
Number of subjects: 165
Study 28545525 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured resection group (externally rotating the axis 3° off the posterior femoral condylar axis)
Number of subjects: 165
Study 28545525 — intervention group
Group type: EXPERIMENTAL
Intervention: Block group (spacer blocks of various thicknesses)
Number of subjects: 165
Study 28545525 — intervention group
Group type: COMPARATOR
Intervention: All groups (postoperative 2 year clinical results)
Number of subjects: 165
Study 26490109 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based rehabilitation program (GRP)
Number of subjects: 56
Study 26490109 — intervention group
Group type: COMPARATOR
Intervention: Usual physical therapy (comparator group)
Number of subjects: 56
Study 24355115 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI systolic-diastolic range <10°
Number of subjects: 266
Study 24355115 — intervention group
Group type: COMPARATOR
Intervention: Pre-PCI diastolic distal BA tertiles (<82°, 82° to 106°, ≥107°)
Number of subjects: 266
Study 21227454 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS cholecystectomy
Number of subjects: 50
Study 21227454 — intervention group
Group type: COMPARATOR
Intervention: Classic laparoscopic cholecystectomy
Number of subjects: 50
Study 18603026 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg/day
Number of subjects: 18
Study 18603026 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg/day
Number of subjects: 18
Study 17077421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (academic detailing)
Number of subjects: 165
Study 17077421 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention group
Number of subjects: 165
Study 17077421 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban hypertensive patients
Number of subjects: 165
Study 17077421 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined urban and suburban data
Number of subjects: 165
Study 15636221 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma patients (trabeculectomy)
Number of subjects: 48
Study 15636221 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 operated patients with age-related cataract)
Number of subjects: 48
Study 11327056 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sulfate plus autologous bone graft (test)
Number of subjects: 12
Study 11327056 — intervention group
Group type: COMPARATOR
Intervention: Bioabsorbable membrane plus autologous bone graft (control)
Number of subjects: 12
Study 9496009 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback relaxation training
Number of subjects: 60
Study 9496009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 8196151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (5 mg or 10 mg twice a day)
Number of subjects: 66
Study 8196151 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (Control)
Number of subjects: 66
Study 3372432 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 14
Study 3372432 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once daily)
Number of subjects: 14
Study 3372432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30535670 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-fampridine 10 mg twice daily
Number of subjects: 636
Study 30535670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 636
Study 30535670 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-fampridine
Number of subjects: 636
Study 28973344 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (20 ppm decreased to 10 ppm between 72 and 96 hours, then to 5 ppm until completion of therapy for 24 days)
Number of subjects: 451
Study 28973344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrogen)
Number of subjects: 451
Study 28973344 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 451
Study 26411885 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine
Number of subjects: 924
Study 26411885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 924
Study 24573590 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementation by argon plasma coagulation (group 2)
Number of subjects: 21
Study 24573590 — intervention group
Group type: COMPARATOR
Intervention: No additional procedure (group 1)
Number of subjects: 21
Study 21556911 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol D (saline chaser at 8 mL/s)
Number of subjects: 100
Study 21556911 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C (saline chaser at 4 mL/s)
Number of subjects: 100
Study 18482014 — intervention group
Group type: EXPERIMENTAL
Intervention: RCAC (1% formulation applied twice a day for 28 days)
Number of subjects: 124
Study 18482014 — intervention group
Group type: COMPARATOR
Intervention: Placebo (applied twice a day for 28 days)
Number of subjects: 124
Study 18482014 — intervention group
Group type: EXPERIMENTAL
Intervention: RCAC (in vitro treatment)
Number of subjects: 124
Study 18482014 — intervention group
Group type: EXPERIMENTAL
Intervention: RCAC (clinical effectiveness measures)
Number of subjects: 124
Study 17130317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pneumatic leg pump therapy postoperatively
Number of subjects: 200
Study 17130317 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pneumatic leg pump therapy)
Number of subjects: 200
Study 14636811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways intervention
Number of subjects: 1447
Study 14636811 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1447
Study 11007407 — intervention group
Group type: EXPERIMENTAL
Intervention: povidone-iodine
Number of subjects: 30
Study 11007407 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 30
Study 11007407 — intervention group
Group type: COMPARATOR
Intervention: no preparation
Number of subjects: 30
Study 8928893 — intervention group
Group type: EXPERIMENTAL
Intervention: Double pharmacological autonomic blockade with propranolol (0.2 mg/kg iv) and atropine (0.04 mg/kg iv)
Number of subjects: 17
Study 8928893 — intervention group
Group type: EXPERIMENTAL
Intervention: Double pharmacological autonomic blockade with propranolol and atropine
Number of subjects: 17
Study 8928893 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements (no intervention)
Number of subjects: 17
Study 1471411 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit‐whole cell vaccine (B‐WC)
Number of subjects: 90000
Study 1471411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90000
Study 6375258 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 and 2.0 mg)
Number of subjects: 17
Study 6375258 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 17
Study 6375258 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 17
Study 30363012 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (8 weeks)
Number of subjects: 0
Study 30363012 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (10 weeks)
Number of subjects: 0
Study 30363012 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and wellness education classes (10 weeks)
Number of subjects: 0
Study 30363012 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (attention control)
Number of subjects: 0
Study 30363012 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 30363012 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 29504877 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive resin cement (RelyX U100/U200)
Number of subjects: 152
Study 29504877 — intervention group
Group type: COMPARATOR
Intervention: Regular resin cement (Single Bond and RelyX ARC)
Number of subjects: 152
Study 27658218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT) alone
Number of subjects: 160
Study 27658218 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavior therapy (CBT) plus medication (zolpidem)
Number of subjects: 160
Study 27658218 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended CBT
Number of subjects: 160
Study 27658218 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT and intermittent medication (prn)
Number of subjects: 160
Study 27658218 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance CBT
Number of subjects: 160
Study 27658218 — intervention group
Group type: COMPARATOR
Intervention: CBT without additional treatment
Number of subjects: 160
Study 25090365 — intervention group
Group type: EXPERIMENTAL
Intervention: Four sessions of Tele-MI
Number of subjects: 100
Study 25090365 — intervention group
Group type: COMPARATOR
Intervention: One session of Tele-MI
Number of subjects: 100
Study 25090365 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study 22475857 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses PENTA, then Dose 4 DTaP and Hib
Number of subjects: 2167
Study 22475857 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 QUAD doses and Hib
Number of subjects: 2167
Study 22475857 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 PENTA doses
Number of subjects: 2167
Study 22475857 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine group (3 doses DTaP, IPV, and Hib and at Dose 4 DTaP and Hib)
Number of subjects: 2167
Study 19249029 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS)
Number of subjects: 0
Study 19249029 — intervention group
Group type: COMPARATOR
Intervention: Control group without PGS
Number of subjects: 0
Study 17084512 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A: vinblastine (0.2 mg/kg on day 1), etoposide (100 mg/m2/d on days 1-5), cisplatin (40 mg/m2/d on days 1-5), and bleomycin (30 mg on days 1, 8, and 15)
Number of subjects: 115
Study 17084512 — intervention group
Group type: COMPARATOR
Intervention: Arm B: etoposide (350 mg/m2/d on days 1-5), cisplatin (40 mg/m2/d on days 1-5), and cyclophosphamide (1600 mg/m2/d on days 2-5)
Number of subjects: 115
Study 17084512 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 115
Study 17084512 — intervention group
Group type: COMPARATOR
Intervention: Arm B
Number of subjects: 115
Study 16218350 — intervention group
Group type: EXPERIMENTAL
Intervention: Detralex (treated for 14 days before and after surgery)
Number of subjects: 181
Study 16218350 — intervention group
Group type: COMPARATOR
Intervention: Not treated with Detralex (control group)
Number of subjects: 181
Study 12097444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentist informed of MDAS score
Number of subjects: 119
Study 12097444 — intervention group
Group type: COMPARATOR
Intervention: Dentist not informed of MDAS score
Number of subjects: 119
Study 10073421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 132
Study 10073421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (61 to 240 mo)
Number of subjects: 132
Study 10073421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (0.7 to 6 mo)
Number of subjects: 132
Study 7675967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol pretreatment (2 days)
Number of subjects: 9
Study 7675967 — intervention group
Group type: COMPARATOR
Intervention: (+)-fenfluramine (30 mg po)
Number of subjects: 9
Study 2105409 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde vapor exposure at levels of 0.85 mg/m3, 0.12 mg/m3, and 0.008 mg/m3 for 90 min
Number of subjects: 15
Study 2105409 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde vapor exposure
Number of subjects: 15
Study 6255005 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (1.2-2.5 mg/day)
Number of subjects: 21
Study 6255005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31836196 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg, increased to 300 mg as tolerated)
Number of subjects: 192
Study 31836196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 30231896 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous (SC) 300 mg crenezumab every 2 weeks for 68 weeks
Number of subjects: 91
Study 30231896 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous (IV) 15 mg/kg crenezumab every 4 weeks for 68 weeks
Number of subjects: 91
Study 30231896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 27431341 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation with problem-solving (PEPS) therapy plus usual treatment
Number of subjects: 306
Study 27431341 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment alone
Number of subjects: 306
Study 27431341 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation with problem-solving (PEPS) therapy
Number of subjects: 306
Study 25514875 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (Group A: 2.62 Joules)
Number of subjects: 72
Study 25514875 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (Group B: 5.24 Joules)
Number of subjects: 72
Study 25514875 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (Group C: 7.86 Joules)
Number of subjects: 72
Study 25514875 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (Group D: 0 Joules)
Number of subjects: 72
Study 25514875 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 72
Study 22661616 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater family organization
Number of subjects: 257
Study 22661616 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater self-efficacy for diabetes management
Number of subjects: 257
Study 22661616 — intervention group
Group type: EXPERIMENTAL
Intervention: More family organization
Number of subjects: 257
Study 19606453 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink plus alcohol
Number of subjects: 27
Study 19606453 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink alone
Number of subjects: 27
Study 19606453 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic, non-caffeinated control beverage
Number of subjects: 27
Study 17453860 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta‐estradiol + 0.1 mg NETA
Number of subjects: 577
Study 17453860 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta‐estradiol + 0.25 mg NETA
Number of subjects: 577
Study 17453860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 15168036 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oils with increasing phenolic concentration (0 to 150 mg/Kg)
Number of subjects: 30
Study 15168036 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil with high phenolic content
Number of subjects: 30
Study 12114917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (3 doses, 800 microg each)
Number of subjects: 12
Study 12114917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12114917 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 12
Study 10049275 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir 4 mg/kg
Number of subjects: 22
Study 10049275 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir 8 mg/kg
Number of subjects: 22
Study 10049275 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir (both doses)
Number of subjects: 22
Study 7586985 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 67
Study 7586985 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (SSZ)
Number of subjects: 67
Study 7586985 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 67
Study 2159264 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur‐Uracil (UFT)
Number of subjects: 76
Study 2159264 — intervention group
Group type: COMPARATOR
Intervention: FT‐207
Number of subjects: 76
Study 2159264 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT
Number of subjects: 76
Study 526385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine i.v. infusion
Number of subjects: 31
Study 31661171 — intervention group
Group type: EXPERIMENTAL
Intervention: Figure-of-eight suture (F8)
Number of subjects: 70
Study 31661171 — intervention group
Group type: COMPARATOR
Intervention: Manual pressure (MP)
Number of subjects: 70
Study 31661171 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 29104459 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (30 g/d)
Number of subjects: 43
Study 29104459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (casein, 30 g/d)
Number of subjects: 43
Study 24519448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy plus laser therapy (ice chips for 1 h 35 min followed by low-level laser therapy, InGaAIP, 660 nm, 40 mW, 6 J/cm(2), n = 54)
Number of subjects: 71
Study 24519448 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy alone (n = 17)
Number of subjects: 71
Study 24519448 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment for OM, n = 33)
Number of subjects: 71